Clinical Trial Update: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase III trial evaluating YL201 for relapsed small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• YL201

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 3 | Status: RECRUITING